NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-034-2018-0-US-08 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE US National Stage 16/971,826 11760790 Issued PDF
NCI E-266-2011-0-EP-37 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage EP DIV 20192082.4 Pending
NCI E-059-2013-0-AU-13 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor AU DIV 2020220209 Abandoned
NEI E-091-2018-0-US-06 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION US National Stage 16/971,288 Pending
NCI E-248-2020-0-EP-04 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer EP National Stage 20855632.4 Pending
NCI E-248-2020-0-PCT-02 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer PCT PCT PCT/US2020/047069 Expired
NIAID E-085-2018-0-US-04 CD153 AND/OR CD30 IN INFECTION US National Stage 16/971,144 Pending
NCI E-248-2020-0-CA-03 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer CA National Stage 3147509 Pending
NCI E-068-2018-0-EP-05 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 EP National Stage 19709154.9 Pending
NCI E-036-2018-0-US-02 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS US National Stage 16/970,155 11787764 Issued PDF
NIA E-139-2012-2-US-15 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES US CON 16/992,742 11389415 Issued PDF
NCI E-046-2019-0-US-06 Non-aggregating Heptamethine Cyanine Fluorophores For In Vivo Imaging US National Stage 16/969,902 10961193 Issued PDF
NIBIB E-054-2018-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING US National Stage 16/969,673 Pending
NIAID E-035-2018-0-US-03 TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS US National Stage 16/968,792 Pending
NIDDK E-028-2018-1-CN-04 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS CN National Stage 201980012696.0 Abandoned
NIDA E-023-2018-0-US-04 DREADD ACTUATORS US National Stage 16/968,437 11739063 Issued PDF
NIDDK E-028-2018-1-CA-03 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS CA National Stage 3090788 Abandoned
NCI E-068-2018-0-CN-04 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 CN National Stage 201980012443.3 Pending
NCI E-068-2018-0-AU-03 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 AU National Stage 2019218785 Pending
NCI E-126-2019-0-PCT-02 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PCT PCT PCT/US2020/45100 Expired
NIDDK E-028-2018-1-JP-06 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS JP National Stage 2020-542580 Abandoned
NCI E-176-2014-0-SA-54 Anti-Human Papillomavirus 16 E7 T Cell Receptors SA DIV 520412601 Pending
NHLBI E-036-2015-1-US-03 NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS US DIV 16/985,797 Pending
NCI E-041-2018-0-US-04 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER US National Stage 16/967,472 Pending
NCI E-068-2018-0-CA-07 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 CA National Stage 3090512 Pending
NCI E-080-2018-0-US-09 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY US National Stage 16/967,302 11904057 Issued PDF
NIDDK E-028-2018-1-US-07 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS US National Stage 16/967,177 11584736 Issued PDF
NCI E-067-2017-0-HK-09 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES HK EP 62020013025.5 Issued
NHLBI E-163-2019-0-PCT-02 Radiolabeled Sugars For Imaging Of Fungal Infections PCT PCT PCT/US2020/044446 Expired
NIA E-092-2011-0-US-12 USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)-KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN US CON 16/945,163 Pending
NHLBI E-163-2019-0-EP-03 Radiolabeled Sugars For Imaging Of Fungal Infections EP National Stage 20757180.3 Pending
NIAID E-147-2015-0-ZA-15 BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST HIV-1 V1V2 ENV REGION ZA DIV 2020/04763 Pending
NCI E-215-2017-0-US-07 STEREOSELECTIVE SYNTHESIS AND PROCESS FOR THE MANUFACTURING OF 2'-DEOXYNUCLEOSIDES US National Stage 16/966,398 11365211 Issued PDF
NCI E-176-2014-0-JP-53 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T-CELL RECEPTOR JP DIV 2020-127833 Issued
NINR E-134-2015-0-US-02 POINT OF NEED TESTING DEVICE AND METHODS OF USE THEREOF US DIV 16/941,333 Pending
NIDDK E-028-2018-1-AU-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS AU National Stage 2019218256 Abandoned
NCI E-227-2017-0-EP-03 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING
A MIXED MODE RESIN COMPOSITION 		EP National Stage 18847175.9 Issued
NCI E-227-2017-0-GB-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING
A MIXED MODE RESIN COMPOSITION 		GB EP 18847175.9 Issued
NCI E-227-2017-0-FR-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING
A MIXED MODE RESIN COMPOSITION 		FR EP 18847175.9 Issued
NCI E-227-2017-0-DE-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING
A MIXED MODE RESIN COMPOSITION 		DE EP 18847175.9 Issued
NCI E-068-2018-0-US-06 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 US National Stage 16/964,796 Pending
NIDDK E-144-2019-2-US-01 Treatment And Prevention Of Neuropathic Pain With P2Y14 Antagonists US ORD 16/936,951 11708346 Issued PDF
NIAID E-033-2018-0-US-06 BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE US National Stage 16/963,718 11369675 Issued PDF
NIAID E-064-2015-3-US-01 MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE US CIP 16/934,573 Pending
NIDDK E-028-2018-1-EP-05 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS EP National Stage 19707559.1 Pending
NCI E-021-2015-0-HK-30 Anti-CD70 Chimeric Antigen Receptors HK EP 42020011615.0 Issued
NCI E-181-2019-0-EP-03 Chimeric Antigen Receptors Containing Glypican 2 Binding Domains EP National Stage 20751027.2 Pending
NCI E-181-2019-0-US-05 Chimeric Antigen Receptors Containing Glypican 2 Binding Domains US National Stage 17/597,580 Pending
NIA E-214-2018-0-US-04 PHENOTYPIC AGE AND DNA METHYLATION BASED BIOMARKERS FOR LIFE EXPECTANCY AND MORBIDITY US National Stage 16/963,065 Pending
NCI E-181-2019-0-CN-01 Chimeric Antigen Receptors Containing Glypican 2 Binding Domains CN National Stage 202080052372.2 Pending